%0 Journal Article
%T Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer.
%A Karacin C
%A Sunar V
%A Urakci Z
%A Yilmaz A
%A Ayhan M
%A Ersoy M
%A Guven DC
%A Erturk I
%A Durmus Y
%A Karacin P
%A Boran N
%A Ustun YE
%A Meydan M
%A Dogan M
%A Oksuzoğlu B
%A Ates O
%A Karaca M
%A Uncu D
%A Ergun Y
%A Arik Z
%J Future Oncol
%V 20
%N 4
%D 2024 Feb 8
%M 38328890
%F 3.674
%R 10.2217/fon-2023-0763
%X Aim: To investigate the efficacy and safety of bevacizumab in patients with recurrent low-grade serous ovarian carcinoma. Materials & methods: The data of patients who received at least two cycles of bevacizumab in combination with chemotherapy were retrospectively recorded. Results: The median age of 51 patients was 56 (range: 33-75) years. The complete response rate was 10.4% and the partial response rate was 43.7%. The objective response rate was 54.1%. Median progression-free survival was 15.9 months (95% CI: 9.1-22.6) and median overall survival was 42.5 months (95% CI: 37.2-47.8). Conclusion: Bevacizumab with chemotherapy is an effective option for treating recurrent ovarian low-grade serous carcinoma.